source
- Iopofosine I-131 shows high response rates and durable disease control in Waldenstrom macroglobulinemia trialThe 12‑month follow‑up from the CLOVER‑WaM study reports that patients receiving Iopofosine I‑131 achieved strong clinical activity in Waldenstrom macroglobulinemia. In the per‑protocol group, the…
- Cytokinetics' Myqorzo meets primary goals in Phase 3 trial for non-obstructive hypertrophic cardiomyopathyCytokinetics announced that its experimental therapy Myqorzo achieved its primary endpoints in a Phase 3 study of patients with non-obstructive hypertrophic cardiomyopathy (HCM). The trial showed…BioPharma Dive · 4mo agoPositive readoutPositive